# TAK valuation — Takeda Pharmaceutical Co Ltd ADR

Equity Rank model valuation · Pharmaceuticals · as of 2026-10-22
Source: https://www.equity-rank.com/stocks/TAK  ·  JSON: https://api.equity-rank.com/api/stocks/TAK/public

No model fair value is published for TAK. TAK reports its financial statements in JPY. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.

| Metric | Value |
|---|---|
| Current price | $20.30 |
| Model fair value estimate | not published |
| Margin-of-safety differential | not published |
| Fundamental Strength (0–100) | 61.1 (grade B-) |
| Next earnings report | 2026-10-29 (before market open) · analyst consensus EPS estimate $0.31 |
| Last recomputed | 2026-10-22 |

## How to quote this page

Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/TAK. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Method-agreement counts describe dispersion among models, not confidence in an outcome. Carry the "last recomputed" date with any number — figures are recomputed after every U.S. market close.

## How the estimate is computed

Equity Rank runs 19 valuation methods (8–15 per security depending on data availability) — including discounted cash flow, Graham Number, price-to-free-cash-flow, Earnings Power Value, three-stage DCF, dividend discount, residual income, and justified price-to-book — and blends the individual outputs into one estimate, weighting each method by its trailing accuracy in the Pharmaceuticals sector. Method definitions: https://www.equity-rank.com/methodology · glossary: https://www.equity-rank.com/glossary.

## Related

- All Healthcare stocks with model fair values: https://www.equity-rank.com/stocks/sector/healthcare
- Peers: JNJ (https://www.equity-rank.com/stocks/JNJ.md), UNH (https://www.equity-rank.com/stocks/UNH.md), PFE (https://www.equity-rank.com/stocks/PFE.md), ABBV (https://www.equity-rank.com/stocks/ABBV.md), MRK (https://www.equity-rank.com/stocks/MRK.md)
- Machine access: MCP server https://api.equity-rank.com/mcp · public JSON https://api.equity-rank.com/api/stocks/TAK/public · https://www.equity-rank.com/developers

Equity Rank is not a registered investment adviser. Every figure on this page is algorithmic model output under stated assumptions, for informational and educational purposes only — not investment advice, not a target price, and not a forecast of results.